Stay updated with breaking news from Nasdaq Vxrt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Vaxart (NASDAQ:VXRT – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. According to Zacks, “Vaxart, Inc. is a clinical-stage company developing a range of oral recombinant vaccines based on its proprietary delivery platform. The […]
Company begins 2022 with multiple active programs with data readouts expected this year Initial data from COVID-19 Phase II study expected in the first...
Pharmaceutical Industry Veteran Brings Broad Legal Expertise to Vaxart Senior Management Team SOUTH SAN FRANCISCO, Calif., Feb. 14, 2022 (GLOBE...
Pharmaceutical Industry Veteran Brings Broad Legal Expertise to Vaxart Senior Management Team SOUTH SAN FRANCISCO, Calif., Feb. 14, 2022 (GLOBE...
Four clinical trials for COVID-19 and norovirus oral tablet vaccine candidates are currently ongoing Company now operates two GMP manufacturing plants to...